The Russell 2000 Index is a small-cap stock market index that includes the bottom 2,000 companies found in the Russell 3000 index. The Russell Microcap Index includes the 1,000 smallest securities found ...

INDIANAPOLIS, May 5, 2020 /PRNewswire/ -- Palmer Trucks is excited to announce that its dealership operations in Louisville will be expanding with the opening of a new full-service dealership in Southern Indiana. The new dealership, Kenworth of Sellersburg, w…

Focused on Novel Combination of Clinical-Grade Exosomes and Hydropeptides for Cosmeceutical and Orthopedic Product DevelopmentSigned Three-Way Material Transfer Agreement.

FREEHOLD, N.J., Jan. 06, 2020 -- Avalon GloboCare Corp. (NASDAQ: AVCO), a clinical-stage global developer of cell-based technologies and therapeutics, today announced its Chief.

It is not uncommon to see companies perform well in the years after insiders buy shares. Unfortunately, there are also...

A look at what happened on May 6 in sports history, including the Kings' improbable four-game sweep of the St. Louis Blues in the Stanley Cup playoffs.

Avalon GloboCare Corp. (AVCO), a leading clinical-stage global developer of cell-based technologies and therapeutics, today announced it has secured a $20 million credit facility provided by the Company’s Chairman, Daniel Lu.  The unsecured credit facility bears interest at a rate of 5% and provides for maturity on drawn loans 36 months after funding. The credit facility will be used to accelerate the Company’s ongoing research and development programs, clinical studies, as well as commercial strategies.

Forms Major Regional Hub in China for CellTech IndustryPartnership Delivers Synergy of Infrastructural Resources for Clinical Development and Bioprocessing Technologies in.

FREEHOLD, N.J., July 22, 2019 -- Avalon GloboCare Corp. (NASDAQ: AVCO), a leading clinical-stage global developer of cell-based technologies and therapeutics, today announced.

Avalon GloboCare to Unveil the Launch of its Exosome Product Commercialization Plan at the Second Aesthetic Industry Conference, the Largest Aesthetics Conference Across Asia Yu Zhou, M.D., Ph.D., Co-CEO ...

RNA-Based Chimeric Antigen Receptor (CAR) Design Compatible with Broad Range of Immune Effector Cells, Including T (CAR-T) and Natural Killer Cells...

Completed Functional Studies of Six QTY Code Designed Variant Cytokine Receptors as “Molecular Mop” to Remove Excessive Cytokines (“Cytokine Storm”) Related to Coronavirus.

FREEHOLD, N.J., Sept. 19, 2019 -- Avalon GloboCare Corp. (NASDAQ: AVCO), a leading global developer of cell-based technologies and therapeutics, today announced it has.

FREEHOLD, N.J., Feb. 24, 2020 -- Avalon GloboCare Corp. (NASDAQ: AVCO), a clinical-stage global developer of cell-based technologies and therapeutics, announced today that it.

FREEHOLD, N.J., June 18, 2019 /PRNewswire/ -- Avalon GloboCare Corp. (AVCO), a leading global developer of cell-based technologies and therapeutics, today announced that it expects to be added to the Russell 3000® Index, based on a preliminary list of additions posted June 7, 2019.  Final inclusion in the Russell 3000® Index will be determined following completion of the annual Russell US Indexes Reconstitution, which occurs after the US equity markets close on Friday, June 28, 2019. Indexes provided by FTSE Russell, a leading global index provider, are widely used by investment managers and institutional investors for index funds and as benchmarks for active investment strategies.  Approximately $9 trillion in assets are benchmarked against the Russell US Indexes. Membership in the Russell Microcap Index remains in place for one year and provides for automatic inclusion in the appropriate growth and value style indexes.  Russell determines membership for its equity indexes primarily by objective, market-capitalization rankings and style attributes.

The big shareholder groups in Avalon GloboCare Corp. (NASDAQ:AVCO) have power over the company. Large companies...

FREEHOLD, N.J., June 26, 2019 -- Avalon GloboCare Corp. (NASDAQ: AVCO), a leading global developer of cell-based technologies and therapeutics, announced today that the Company.

RNA-Based Chimeric Antigen Receptor (CAR) Design Compatible with Broad Range of Immune Effector Cells, Including T (CAR-T) and Natural Killer Cells (CAR-NK) Without the Use of.

FREEHOLD, N.J., July 22, 2019 -- Avalon GloboCare Corp. (NASDAQ: AVCO), a leading clinical-stage global developer of cell-based technologies and therapeutics, today announced.

CD19 CAR-T candidate, AVA-001, has entered first-in-human clinical study for relapsed/refractory B-cell acute lymphoblastic leukemia and non-Hodgkin lymphoma in July.

FREEHOLD, NJ / ACCESSWIRE / November 20, 2019 / Avalon GloboCare Corp. (NASDAQ:AVCO), a leading global developer of cell-based technologies and therapeutics, today announced that management will present ...

While 1979’s anthemic “We Are Family” broke Sister Sledge into the mainstream, Kathy Sledge and her older sisters Debbie, Joni, and Kim were hardly overnight sensations. They paid their dues, and had been recording for Atco Records since 1973 when all four me…

Palmer Trucks is excited to announce that its dealership operations in Louisville will be expanding with the opening of a new full-service dealership in Southern Indiana. The new dealership, Kenworth of Sellersburg, will be located at 1503 Avco Blvd. Sellersb…

FREEHOLD, N.J., Feb. 04, 2020 -- Avalon GloboCare Corp. (NASDAQ: AVCO), a clinical-stage global developer of cell-based technologies and therapeutics, announced today that its.

FREEHOLD, N.J., Oct. 21, 2019 -- Avalon GloboCare Corp. (NASDAQ: AVCO), a leading global developer of cell-based technologies and therapeutics, today announced plans to.